Exact Mass: 565.2496

Exact Mass Matches: 565.2496

Found 500 metabolites which its exact mass value is equals to given mass value 565.2496, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

Ipecoside

Methyl (2S,3R,4S)-4-[[(1R)-2-acetyl-1,2,3,4-tetrahydro-6,7-dihydroxy-1-isoquinolinyl]methyl]-3-ethenyl-2-(β-D-glucopyranosyloxy)-3,4-dihydro-2H-pyran-5-carboxylate

C27H35NO12 (565.2159)

Ipecoside is a terpene glycoside. Ipecoside is a natural product found in Carapichea ipecacuanha with data available. Methyl (2S,3R,4S)-4-[[(1R)-2-acetyl-1,2,3,4-tetrahydro-6,7-dihydroxy-1-isoquinolinyl]methyl]-3-ethenyl-2-(β-D-glucopyranosyloxy)-3,4-dihydro-2H-pyran-5-carboxylate. CAS Common Chemistry. CAS, a division of the American Chemical Society, n.d. https://commonchemistry.cas.org/detail?cas_rn=15401-60-2 (retrieved 2024-07-09) (CAS RN: 15401-60-2). Licensed under the Attribution-Noncommercial 4.0 International License (CC BY-NC 4.0). Ipecoside is an alkaloid isolated from Psychotria[1].

Coelichelin

C21H39N7O11 (565.2707)

A tetrapeptide hydroxamate siderophore that is isolated from Streptomyces coelicolor.

Acrimarine I

6,11-dihydroxy-12-[1-(7-methoxy-2-oxo-2H-chromen-6-yl)-3-methylbut-2-en-1-yl]-2,2,5-trimethyl-5,10-dihydro-2H-1-oxa-5-azatetraphen-10-one

C34H31NO7 (565.21)

Acrimarine I is found in citrus. Acrimarine I is an alkaloid from roots of Yalaha. Alkaloid from roots of Yalaha. Acrimarine I is found in citrus.

Hemorphin-4

(2S,3R)-2-{[(2S)-2-({[(2S)-1-[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]pyrrolidin-2-yl](hydroxy)methylidene}amino)-1-hydroxy-3-(1H-indol-3-yl)propylidene]amino}-3-hydroxybutanoic acid

C29H35N5O7 (565.2536)

Hemorphin-4 is an endogenous 4-residue opioid peptide of the hemorphin family which possesses antinociceptive properties. It has the amino acid sequence Tyr-Pro-Trp-Thr. It is derived from the β-chain of hemoglobin in the bloodstream. Hemorphin-4 has affinities for the μ-, δ-, and κ-opioid receptors that are in the same range as the structurally related β-casomorphins, although affinity to the κ-opioid receptor is markedly higher in comparison. It acts as an agonist at these sites. Hemorphin-4 also has inhibitory effects on angiotensin-converting enzyme (ACE).

(2-Amino-3-methylphenyl)-[4-[4-[[2-(3-chlorophenyl)sulfonylphenyl]methyl]piperidin-1-yl]piperidin-1-yl]methanone

(2-Amino-3-methylphenyl)-[4-[4-[[2-(3-chlorophenyl)sulphonylphenyl]methyl]piperidin-1-yl]piperidin-1-yl]methanone

C31H36ClN3O3S (565.2166)

Cinaciguat

4-{[(4-carboxybutyl)[2-(2-{[4-(2-phenylethyl)phenyl]methoxy}phenyl)ethyl]amino]methyl}benzoic acid

C36H39NO5 (565.2828)

2-[[(2S)-1-[(2S)-2-[[(2S)-1-[(2S)-2-Amino-3-(4-hydroxyphenyl)propanoyl]pyrrolidin-2-yl]methylamino]-3-phenylpropanoyl]pyrrolidine-2-carbonyl]amino]acetic acid

C30H39N5O6 (565.29)

N-Formyl-met-leu-phe-lys

6-amino-2-(2-{2-[2-formamido-4-(methylsulfanyl)butanamido]-4-methylpentanamido}-3-phenylpropanamido)hexanoic acid

C27H43N5O6S (565.2934)

Lac Dye

2-{[6-(4-{2-[4-(dimethylamino)phenyl]diazen-1-yl}phenoxy)-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol

C26H35N3O11 (565.2271)

Tyr Ile Arg Asp

(2S)-2-[(2S)-2-[(2S,3S)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]-3-methylpentanamido]-5-carbamimidamidopentanamido]butanedioic acid

C25H39N7O8 (565.286)

Phe Asp Thr Gly Leu

C26H39N5O9 (565.2748)

Val Tyr Arg Glu

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-methylbutanamido]-3-(4-hydroxyphenyl)propanamido]-5-carbamimidamidopentanamido]pentanedioic acid

C25H39N7O8 (565.286)

Glu Arg Phe Asp

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-4-carboxybutanamido]-5-carbamimidamidopentanamido]-3-phenylpropanamido]butanedioic acid

C24H35N7O9 (565.2496)

Phe Glu Arg Asp

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-phenylpropanamido]-4-carboxybutanamido]-5-carbamimidamidopentanamido]butanedioic acid

C24H35N7O9 (565.2496)

Thr Ala Phe Val Glu

C26H39N5O9 (565.2748)

C27H35NO12_Methyl (2S,3R,4S)-4-{[(1R)-2-acetyl-6,7-dihydroxy-1,2,3,4-tetrahydro-1-isoquinolinyl]methyl}-2-(beta-D-glucopyranosyloxy)-3-vinyl-3,4-dihydro-2H-pyran-5-carboxylate

Trp His Ser His

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]-3-(1H-imidazol-4-yl)propanamido]-3-hydroxypropanamido]-3-(1H-imidazol-4-yl)propanoic acid

C26H31N9O6 (565.2397)

Trp Ile Phe Thr

(2S,3R)-2-[(2S)-2-[(2S,3S)-2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]-3-methylpentanamido]-3-phenylpropanamido]-3-hydroxybutanoic acid

C30H39N5O6 (565.29)

C32H39NO8 (565.2676)

7-O-acetyl-19,20-epoxycytochalasin D

C32H39NO8 (565.2676)

disodium 1-[2-[(12-hydroxy-1-oxooctadec-9-enyl)amino]ethyl] 2-sulphosuccinate

C24H41NNa2O9S (565.2297)

Cicortonide

C29H37ClFNO7 (565.2242)

Fibrinogen-Binding Peptide

C25H39N7O8 (565.286)

Fibrinogen-Binding Peptide (designed by anticomplementarity hypothesis) is a presumptive peptide mimic of the vitronectin binding site on the fibrinogen receptor. Fibrinogen-Binding Peptide binds fibrinogen and inhibits both the adhesion of platelets to fibrinogen and platelet aggregation, and also inhibits the adhesion of platelets to vitronectin[1].

For-Met-Leu-Phe-Lys-OH

C27H43N5O6S (565.2934)

N-Formyl-Met-Leu-Phe-Lys (fMLFK) is a peptide, acts as a potent and selective agonist of FPR1, with EC50s of 3.5 nM, 6.7 μM and 0.88 μM for FPR1, FPR2 and FPR2-D2817.32G, respectively[1].

Dicon

C18H39N5O13S (565.2265)

Dexofen

dextropropoxyphene napsylate

C32H39NO6S (565.2498)

C78272 - Agent Affecting Nervous System > C67413 - Opioid Receptor Agonist

Cinaciguat

C36H39NO5 (565.2828)

C78274 - Agent Affecting Cardiovascular System > C29707 - Vasodilating Agent

Lumateperone Tosylate

C31H36FN3O4S (565.241)

C78272 - Agent Affecting Nervous System > C29710 - Antipsychotic Agent Lumateperone (ITI-007) tosylate is a 5-HT2A receptor antagonist (Ki = 0.54 nM), a partial agonist of presynaptic D2 receptors and an antagonist of postsynaptic D2 receptors (Ki = 32 nM), and a dopamine D1 receptor modulator. Lumateperone tosylate has anticancer activity and can also be used in studies of psychiatric disorders such as schizophrenia[1][2][3].

Befetupitant

C29H29F6N3O2 (565.2164)

C78272 - Agent Affecting Nervous System > C265 - Antidepressant Agent

Lac Dye

C26H35N3O11 (565.2271)

2-[[(2S)-1-[(2S)-2-[[(2S)-1-[(2S)-2-Amino-3-(4-hydroxyphenyl)propanoyl]pyrrolidin-2-yl]methylamino]-3-phenylpropanoyl]pyrrolidine-2-carbonyl]amino]acetic acid

C30H39N5O6 (565.29)

alpha-Verdoheme

C33H33N4O5+ (565.2451)

(1R,2R)-1-benzyl-3-(dimethylamino)-2-methyl-1-phenylpropyl propanoate naphtalene-2-sulfonic acid

A 2-acyl-sn-glycero-3-phosphoethanolamine zwitterion obtained by transfer of a proton from the phosphate to the amino group of 2-[(9S,11R)-epidioxy-15(S)-hydroperoxy-(5Z,13E)-prostadienoyl]-sn-glycero-3-phosphoethanolamine; major species at pH 7.3.

4-{[4-(dimethylamino)phenyl]diazenyl}phenyl-beta-lactoside

C26H35N3O11 (565.2271)

A glycoside comprising beta-lactose having a p-(p-dimethylaminophenylazo)phenyl group at the 1-position.

2-[(9S,11R)-epidioxy-(15S)-hydroperoxy-(5Z,13E)-prostadienoyl]-sn-glycero-3-phosphoethanolamine

JNJ-31020028

C34H36FN5O2 (565.2853)

JNJ-31020028 is a selective and brain penetrant antagonist of neuropeptide Y Y2 receptor with pIC50 values of 8.07 and 8.22 for human and rat Y2 receptor, respectively. JNJ-31020028 can be used for the research of nervous disease[1].

MK-4074

C33H31N3O6 (565.2213)

MK-4074 is a liver-specific inhibitor of acetyl-CoA carboxylase ACC1 and ACC2 with IC50 values of approximately 3 nM.

Z-Ala-Ala-Asn-AMC

C28H31N5O8 (565.2173)

Z-Ala-Ala-Asn-AMC (Cbz-Ala-Ala-Asn-AMC) is the legumain substrate. Overexpressed legumain in 293 HEK-Leg cells potently cleaved CBZ-Ala-Ala-Asn-AMC[1].

2-(1-amino-6-{[(2,3-dihydroxyphenyl)(hydroxy)methylidene]amino}hexan-2-yl)-3,7,8-trihydroxy-1-oxo-4-phenyl-4h-isoquinoline-3-carboxylic acid

C29H31N3O9 (565.206)

methyl 4-[(2-acetyl-5,6-dihydroxy-3,4-dihydro-1h-isoquinolin-3-yl)methyl]-5-ethenyl-6-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5,6-dihydro-4h-pyran-3-carboxylate

C27H35NO12 (565.2159)

2-{[2-amino-1-hydroxy-5-(n-hydroxyformamido)pentylidene]amino}-5-(2-{[2-amino-1-hydroxy-5-(n-hydroxyformamido)pentylidene]amino}-n,3-dihydroxybutanamido)pentanoic acid

C21H39N7O11 (565.2707)

(4r)-2-[(1s)-1-hydroxy-1-[(2r,4s)-2-[(4r)-2-(2-hydroxy-6-pentylphenyl)-4,5-dihydro-1,3-thiazol-4-yl]-3-methyl-1,3-thiazolidin-4-yl]-2-methylpropan-2-yl]-4-methyl-5h-1,3-thiazole-4-carboxylic acid

C27H39N3O4S3 (565.2103)

(4r)-2-[(1r)-1-hydroxy-1-[(2r,4r)-2-[(4r)-2-(2-hydroxy-6-pentylphenyl)-4,5-dihydro-1,3-thiazol-4-yl]-3-methyl-1,3-thiazolidin-4-yl]-2-methylpropan-2-yl]-4-methyl-5h-1,3-thiazole-4-carboxylic acid

C27H39N3O4S3 (565.2103)

[6,9-bis(acetyloxy)-5a,8,11a-trimethyl-1-oxo-3-(pyridin-3-yl)-6,7,7a,9,10,11-hexahydro-2,5-dioxatetraphen-8-yl]methyl acetate

C31H35NO9 (565.2312)

3-({3-[(2-amino-1-hydroxy-4-methylpentylidene)amino]-1-hydroxy-5-(n-methylcarbamimidamido)pentylidene}amino)-6-[2-hydroxy-5-(hydroxymethyl)-4-iminopyrimidin-1-yl]-3,6-dihydro-2h-pyran-2-carboxylic acid

3-({3-[(2-amino-1-hydroxy-4-methylpentylidene)amino]-1-hydroxy-5-(n-methylcarbamimidamido)pentylidene}amino)-6-[2-hydroxy-5-(hydroxymethyl)-4-iminopyrimidin-1-yl]-3,6-dihydro-2h-pyran-2-carboxylic acid

C24H39N9O7 (565.2972)

(1r,2s,3s,5s,6r,8s,10e,12r,13s,16r,17s)-13-(acetyloxy)-17-benzyl-6,19-dihydroxy-6,8,14,15-tetramethyl-7-oxo-4-oxa-18-azatetracyclo[10.7.0.0¹,¹⁶.0³,⁵]nonadeca-10,14,18-trien-2-yl acetate

C32H39NO8 (565.2676)

(4s)-2-[(1r)-1-hydroxy-1-[(2r,4r)-2-[(4r)-2-(2-hydroxy-6-pentylphenyl)-4,5-dihydro-1,3-thiazol-4-yl]-3-methyl-1,3-thiazolidin-4-yl]-2-methylpropan-2-yl]-4-methyl-5h-1,3-thiazole-4-carboxylic acid

C27H39N3O4S3 (565.2103)

(3s,6r,9r,12s,14e,16r,18r)-6-[(3-chloro-4-hydroxyphenyl)methyl]-5,11-dihydroxy-3-(hydroxymethyl)-7,9,12,14,16,18-hexamethyl-1-oxa-4,7,10-triazacyclooctadeca-4,10,14-triene-2,8-dione

C28H40ClN3O7 (565.2555)

6,11-dihydroxy-12-[(1s)-1-(7-methoxy-2-oxochromen-6-yl)-3-methylbut-2-en-1-yl]-2,2,5-trimethyl-1-oxa-5-azatetraphen-10-one

C34H31NO7 (565.21)

methyl (4s,5s,6r)-4-{[(1r)-2-acetyl-7,8-dihydroxy-3,4-dihydro-1h-isoquinolin-1-yl]methyl}-5-ethenyl-6-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5,6-dihydro-4h-pyran-3-carboxylate

methyl (4s,5s,6r)-4-{[(1r)-2-acetyl-7,8-dihydroxy-3,4-dihydro-1h-isoquinolin-1-yl]methyl}-5-ethenyl-6-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5,6-dihydro-4h-pyran-3-carboxylate

C27H35NO12 (565.2159)

(4s)-2-[(1s)-1-hydroxy-1-[(2r,4s)-2-[(4r)-2-(2-hydroxy-6-pentylphenyl)-4,5-dihydro-1,3-thiazol-4-yl]-3-methyl-1,3-thiazolidin-4-yl]-2-methylpropan-2-yl]-4-methyl-5h-1,3-thiazole-4-carboxylic acid

C27H39N3O4S3 (565.2103)

methyl (4s,5r,6s)-4-{[(1r)-2-acetyl-7,8-dihydroxy-3,4-dihydro-1h-isoquinolin-1-yl]methyl}-5-ethenyl-6-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5,6-dihydro-4h-pyran-3-carboxylate

methyl (4s,5r,6s)-4-{[(1r)-2-acetyl-7,8-dihydroxy-3,4-dihydro-1h-isoquinolin-1-yl]methyl}-5-ethenyl-6-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5,6-dihydro-4h-pyran-3-carboxylate

C27H35NO12 (565.2159)

(2s)-2-{[(2r)-2-amino-1-hydroxy-5-(n-hydroxyformamido)pentylidene]amino}-5-[(2r,3r)-2-{[(2r)-2-amino-1-hydroxy-5-(n-hydroxyformamido)pentylidene]amino}-n,3-dihydroxybutanamido]pentanoic acid

C21H39N7O11 (565.2707)

(1r,2s,3s,5s,6r,8s,10e,12r,13s,15s,16r,17s)-13-(acetyloxy)-17-benzyl-6,19-dihydroxy-6,8,15-trimethyl-14-methylidene-7-oxo-4-oxa-18-azatetracyclo[10.7.0.0¹,¹⁶.0³,⁵]nonadeca-10,18-dien-2-yl acetate

(1r,2s,3s,5s,6r,8s,10e,12r,13s,15s,16r,17s)-13-(acetyloxy)-17-benzyl-6,19-dihydroxy-6,8,15-trimethyl-14-methylidene-7-oxo-4-oxa-18-azatetracyclo[10.7.0.0¹,¹⁶.0³,⁵]nonadeca-10,18-dien-2-yl acetate

C32H39NO8 (565.2676)

(4s)-2-[(1s)-1-hydroxy-1-[(2r,4r)-2-[(4r)-2-(2-hydroxy-6-pentylphenyl)-4,5-dihydro-1,3-thiazol-4-yl]-3-methyl-1,3-thiazolidin-4-yl]-2-methylpropan-2-yl]-4-methyl-5h-1,3-thiazole-4-carboxylic acid

C27H39N3O4S3 (565.2103)

3-{[hydroxy([(2r,3r,4s,5r,6s)-3,4,5-trihydroxy-6-(c-hydroxycarbonimidoyl)oxan-2-yl]oxy)phosphoryl]oxy}-2-{[(2z,6e)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl]oxy}propanoic acid

C24H40NO12P (565.2288)

methyl (6s)-4-{[(1r)-2-acetyl-6,7-dihydroxy-3,4-dihydro-1h-isoquinolin-1-yl]methyl}-5-ethenyl-6-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5,6-dihydro-4h-pyran-3-carboxylate

C27H35NO12 (565.2159)

methyl (4s,5r,6s)-4-{[(3r)-2-acetyl-5,6-dihydroxy-3,4-dihydro-1h-isoquinolin-3-yl]methyl}-5-ethenyl-6-{[(2r,3s,4r,5r,6s)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5,6-dihydro-4h-pyran-3-carboxylate

methyl (4s,5r,6s)-4-{[(3r)-2-acetyl-5,6-dihydroxy-3,4-dihydro-1h-isoquinolin-3-yl]methyl}-5-ethenyl-6-{[(2r,3s,4r,5r,6s)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5,6-dihydro-4h-pyran-3-carboxylate

C27H35NO12 (565.2159)

(3s,6r,9s,12s,14e,16r,18s)-6-[(3-chloro-4-hydroxyphenyl)methyl]-5,11-dihydroxy-3-(hydroxymethyl)-7,9,12,14,16,18-hexamethyl-1-oxa-4,7,10-triazacyclooctadeca-4,10,14-triene-2,8-dione

C28H40ClN3O7 (565.2555)

3-{[hydroxy([3,4,5-trihydroxy-6-(c-hydroxycarbonimidoyl)oxan-2-yl]oxy)phosphoryl]oxy}-2-[(3,7,11-trimethyldodeca-2,6,10-trien-1-yl)oxy]propanoic acid

C24H40NO12P (565.2288)

2-(1-hydroxy-1-{2-[2-(2-hydroxy-6-pentylphenyl)-4,5-dihydro-1,3-thiazol-4-yl]-3-methyl-1,3-thiazolidin-4-yl}-2-methylpropan-2-yl)-4-methyl-5h-1,3-thiazole-4-carboxylic acid

C27H39N3O4S3 (565.2103)

(3s,4r)-2-[(2s)-1-amino-6-{[(2,3-dihydroxyphenyl)(hydroxy)methylidene]amino}hexan-2-yl]-3,7,8-trihydroxy-1-oxo-4-phenyl-4h-isoquinoline-3-carboxylic acid

C29H31N3O9 (565.206)

(4s)-2-[(1r)-1-hydroxy-2-methyl-1-[(2r,4r)-3-methyl-2-[(4r)-2-[(1e)-6-oxo-2-pentylcyclohexa-2,4-dien-1-ylidene]-1,3-thiazolidin-4-yl]-1,3-thiazolidin-4-yl]propan-2-yl]-4-methyl-5h-1,3-thiazole-4-carboxylic acid

(4s)-2-[(1r)-1-hydroxy-2-methyl-1-[(2r,4r)-3-methyl-2-[(4r)-2-[(1e)-6-oxo-2-pentylcyclohexa-2,4-dien-1-ylidene]-1,3-thiazolidin-4-yl]-1,3-thiazolidin-4-yl]propan-2-yl]-4-methyl-5h-1,3-thiazole-4-carboxylic acid

C27H39N3O4S3 (565.2103)

methyl 4-[(2-acetyl-6,7-dihydroxy-3,4-dihydro-1h-isoquinolin-1-yl)methyl]-5-ethenyl-6-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5,6-dihydro-4h-pyran-3-carboxylate

C27H35NO12 (565.2159)